Mohammed Haneefa Nizamudeen
- A phase 3 trial examining Novo Nordisk’s (NVO) GLP-1 medicine semaglutide as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) met its primary endpoints.
- Those endpoints were significant improvement in liver fibrosis with no worsening of steatohepatitis, and no worsening of liver
